miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib
Joint Authors
Svoboda, Marek
Hezova, Renata
Slaby, Ondrej
Merhautova, Jana
Kovarikova, Alena
Radova, Lenka
Vyzula, Rostislav
Demlova, Regina
Poprach, Alexandr
Source
Issue
Vol. 2015, Issue 2015 (31 Dec. 2015), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2015-05-03
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
Background.
Sunitinib is a tyrosine kinase inhibitor used in the treatment of metastatic renal cell carcinoma.
The main difficulty related to the treatment is the development of drug resistance followed by rapid progression of the disease.
We analyzed tumor tissue of sunitinib treated patients in order to find miRNAs associated with therapeutic response.
Methods.
A total of 79 patients with metastatic renal cell carcinoma were included in our study.
miRNA profiling in tumor tissue samples was performed by TaqMan Low Density Arrays and a group of selected miRNAs (miR-155, miR-374-5p, miR-324-3p, miR-484, miR-302c, and miR-888) was further validated by qRT-PCR.
Normalized data were subjected to ROC and Kaplan-Meier analysis.
Results.
We reported decreased tissue levels of miR-155 and miR-484 as significantly associated with increased time to progression (miR-155: median TTP 5.8 versus 12.8 months, miR-484: median TTP 5.8 versus 8.9 months).
Conclusion.
miR-155 and miR-484 are potentially connected with sunitinib resistance and failure of the therapy.
miR-155 is a known oncogene with direct influence on neovascularization.
Biological role of miR-484 has to be clarified.
Stratification of patients based on miRNA analysis would allow more personalized approach in therapy of metastatic renal cell carcinoma.
American Psychological Association (APA)
Merhautova, Jana& Hezova, Renata& Poprach, Alexandr& Kovarikova, Alena& Radova, Lenka& Svoboda, Marek…[et al.]. 2015. miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib. BioMed Research International،Vol. 2015, no. 2015, pp.1-5.
https://search.emarefa.net/detail/BIM-1057324
Modern Language Association (MLA)
Merhautova, Jana…[et al.]. miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib. BioMed Research International No. 2015 (2015), pp.1-5.
https://search.emarefa.net/detail/BIM-1057324
American Medical Association (AMA)
Merhautova, Jana& Hezova, Renata& Poprach, Alexandr& Kovarikova, Alena& Radova, Lenka& Svoboda, Marek…[et al.]. miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib. BioMed Research International. 2015. Vol. 2015, no. 2015, pp.1-5.
https://search.emarefa.net/detail/BIM-1057324
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1057324